Themis Medicare Ltd
Themis Medicare Ltd Q2 FY26 Results & Presentation Highlights: Revenue ₹77.99 Cr, PAT ₹14.29 Cr
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Themis Medicare Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) - H1 FY26 Net Revenue: ₹175.57 Cr, down 26.8% YoY from ₹240.0 Cr in H1 FY25 (Page 9) - API business showed growth in Quarter (Q2 FY26) Financials vs Q2 FY25: - EBITDA: ₹(3.09) Cr, down 118.0% YoY (Q2 FY25: ₹17.13 Cr) - EBITDA Margin: (3.96)%, down from 14.6% YoY - PAT: ₹(3.62) Cr, down 125.3% YoY (Q2 FY25: ₹14.29 Cr) - PAT Margin: (4.64)%, down from 12.2% YoY - Operating Margin: - EBITDA margin for Q2 FY26 is negative at (3.96)%.
From Themis Medicare Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8)
- H1 FY26 Net Revenue: ₹175.57 Cr, down 26.8% YoY from ₹240.0 Cr in H1 FY25 (Page 9)
- API business showed growth in the half year with a 31% YoY increase; Trade business increased 4% (Page 5)
- Formulations business faced headwinds negatively impacting top line (Page 8)
- No explicit forward-looking revenue or volume guidance given; management expects positive regulatory developments by March 2026 (Page 5)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key investor presentation takeaways from Morepen Laboratories Ltd's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key investor presentation takeaways from Jubilant Pharmova Ltd's Q2 FY26 investor presentation — and how it ranks against
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY26 investor presen
- Lincoln Pharmaceuticals Ltd (Q2 FY26)
EBITDA: ₹2,927 Crore, a YoY increase of 10.4% . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY26 investor presentation — and how i
Frequently Asked Questions
What were Themis Medicare Ltd Q2 FY26 results?
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) - H1 FY26 Net Revenue: ₹175.57 Cr, down 26.8% YoY from ₹240.0 Cr in H1 FY25 (Page 9) - API business showed growth in Quarter (Q2 FY26) Financials vs Q2 FY25: - EBITDA: ₹(3.09) Cr, down 118.0% YoY (Q2 FY25: ₹17.13 Cr) - EBITDA Margin: (3.96)%, down from 14.6% YoY - PAT: ₹(3.62) Cr, down 125.3% YoY (Q2 FY25: ₹14.29 Cr) - PAT Margin: (4.64)%, down from 12.2% YoY - Operating Margin: - EBITDA margin for Q2 FY26 is negative at (3.96)%.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Is Themis Medicare Ltd planning capital expenditure?
The investor presentation does not explicitly mention any specific capex amounts, capacity expansion figures, new plant projects, or detailed timelines for such initiatives.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.